Metoclopramide in the Treatment of Diabetic Gastroparesis

Allen Lee; Braden Kuo


Expert Rev Endocrinol Metab. 2010;5(5):653-662. 

In This Article

Five-year View

In 5 years' time, hopefully prospective studies looking into the prevalence of TD from metoclopramide will be available. In addition, potential agents targeting 5-HT4 receptors as well as gastric dysrhythmias will be emerging and comparison with the efficacy and safety of metoclopramide will be evaluated. Other formulations may also prove to have a greater tolerability and increase bioavailability leading to decreased side effects.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.